Literature DB >> 22465467

Anorexia nervosa, autoimmunity and the hygiene hypothesis.

Meghan J Acres1, Joseph J Heath, James A Morris.   

Abstract

The hypothesis proposed is that anorexia nervosa (AN) is an autoimmune disease caused by delayed exposure to common micro-organisms in which auto-antibodies to regulatory peptides and hypothalamic neurons, which cross react with microbial antigens, disturb appetite and lead to decreased intake of food. IgG, IgA and IgM auto-antibodies to a range of regulatory peptides concerned with appetite and mood are found in patients with AN. The regulatory peptides show sequence homology with common micro-organisms of the microbial flora. Auto-antibodies to α melanocyte stimulating hormone (αMSH) are positively correlated with AN psychopathology. But patients with bulimia nervosa (BN) and normal healthy controls also have a similar range of auto-antibodies at comparable levels. The incidence of AN is rising in developed countries, the disease is more common in females than in males, the peak incidence is in the teenage years, there is seasonal variation in the month of birth and the disease is more common in higher socio-economic groups. These are all features which are consistent with the hygiene hypothesis. But there is no evidence that the disease is more common in first born than in later born children. There is a paucity of data on early life events such as attendance at nursery and exposure to pets. Genetic factors are important but the data on major histocompatibility complex (MHC) gene polymorphisms are contradictory. The epidemiological and serological data are consistent with the hypothesis under investigation but key questions in relation to the hygiene hypothesis have not been posed. A large case control study of AN epidemiology is indicated. MHC gene polymorphisms should be assessed. There is, however, sufficient evidence to justify a trial of pooled immunoglobulin therapy in patients with life threatening AN.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22465467     DOI: 10.1016/j.mehy.2012.03.002

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  5 in total

1.  Bacterial ClpB heat-shock protein, an antigen-mimetic of the anorexigenic peptide α-MSH, at the origin of eating disorders.

Authors:  N Tennoune; P Chan; J Breton; R Legrand; Y N Chabane; K Akkermann; A Järv; W Ouelaa; K Takagi; I Ghouzali; M Francois; N Lucas; C Bole-Feysot; M Pestel-Caron; J-C do Rego; D Vaudry; J Harro; E Dé; P Déchelotte; S O Fetissov
Journal:  Transl Psychiatry       Date:  2014-10-07       Impact factor: 6.222

2.  An Adolescent Boy with Comorbid Anorexia Nervosa and Hashimoto Thyroiditis.

Authors:  Melis Pehlivantürk Kızılkan; Nuray Kanbur; Sinem Akgül; Ayfer Alikaşifoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12-18

3.  Increased risk of somatic diseases following anorexia nervosa in a controlled nationwide cohort study.

Authors:  Hans-Christoph Steinhausen; Martin Dalgaard Villumsen; Kirsten Hørder; Laura Al-Dakhiel Winkler; Niels Bilenberg; René Klinkby Støving
Journal:  Int J Eat Disord       Date:  2022-04-22       Impact factor: 5.791

4.  Anti-hypothalamus autoantibodies in anorexia nervosa: a possible new mechanism in neuro-physiological derangement?

Authors:  Andrea Escelsior; Ludovica Cogorno; Samir G Sukkar; Andrea Amerio; Lorenzo M Donini; Marina Bellomo; Erika Iervasi; Mario Amore; Daniele Saverino
Journal:  Eat Weight Disord       Date:  2022-03-16       Impact factor: 3.008

Review 5.  The role of "mixed" orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa.

Authors:  Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova
Journal:  Int J Endocrinol       Date:  2013-09-09       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.